Background: The purpose of this study is to undertake a comprehensive systematic review to describe multilevel factors (barriers and facilitators) that may influence the implementation of low-dose chest computed tomography for lung cancer screening in the United States.
Methods: Systematic literature searches were performed using 6 online databases and citation indexes for peer-reviewed studies, for articles published from 2013 to 2021. Studies were classified into 3 perspectives, based on the study's unit of analysis: system, health-care provider, and patient. Barriers and facilitators identified for each study included in our final review were then coded and categorized using the Consolidate Framework for Implementation Research domains.
Results: At the system level, the 2 most common constructs were external policy and incentives and executing the implementation process. At the provider level, the most common constructs were evidence strength and quality of the intervention characteristics, patient needs and resources, implementation climate, and an individual's knowledge and beliefs about the intervention. At the patient level, the most common constructs were patient needs and resources, individual's knowledge and beliefs about the intervention, and engaging in the implementation process. These constructs can act as facilitators or barriers to lung cancer screening implementation.
Conclusions: Applying the Consolidate Framework for Implementation Research domains and constructs to understand and specify factors facilitating uptake of lung cancer screening as well as cataloging the lessons learned from previous efforts helps inform the development and implementation processes of lung cancer screening programs in the community setting.
Registration: PROSPERO, CRD42021247677.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664175 | PMC |
http://dx.doi.org/10.1093/jnci/djac154 | DOI Listing |
J Cardiothorac Surg
January 2025
Thoracic Surgery Unit, Careggi University Hospital, Largo Brambilla, 1, 50134, Florence, Italy.
Background: Lung cancer is the first cause of cancer-related death. Awake lung resection is a new frontier of the concept of minimally invasive surgery. Our purpose is to demonstrate the feasibility of this technique for lobar and sublobar lung resection in NSCLC patients.
View Article and Find Full Text PDFBackground: Metabolic pathways are known to significantly impact the development and advancement of lung cancer. This study sought to establish a signature related to butyrate metabolism that is specifically linked to lung adenocarcinoma (LUAD).
Methods: For the purpose of identifying butyrate metabolism-related differentially expressed genes (BMR-DEGs) in the TCGA-LUAD dataset, we introduced transcriptome data.
Discov Oncol
January 2025
Spinal Surgery Department, the Fourth People's Hospital of Jinan, No.50 Normal Road, Tianqiao District, Jinan, 250031, Shandong, China.
Background: It is known that genomic instability contributes to cancer development. Mitotically associated long non-coding RNA (MANCR) has been reported to promote genomic stability, suggesting its involvement in cancers. Therefore, this study was conducted to investigate the role of MANCR in non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFDiscov Oncol
January 2025
The School Public Health, Fujian Medical University, Fuzhou, 350122, Fujian, China.
The prognosis and treatment efficacy of lung adenocarcinoma (LUAD), a disease with a high incidence, remains unsatisfactory. Identifying new biomarkers and therapeutic targets for LUAD is essential. Chromosomal assembly factor 1B (CHAF1B), a p60 component of the CAF-1 complex, is closely linked to tumor incidence and cell proliferation.
View Article and Find Full Text PDFDiscov Oncol
January 2025
Respiratory Department, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua, 310053, Zhejiang, China.
Background: Plasma proteins contribute to the identification, diagnosis, and prognosis of human illnesses, which may be conducive to understanding the molecular mechanism and diagnosis of Lung adenocarcinoma (LUAD).
Methods: We collected plasma samples from 28 healthy individuals (H) and 56 LUAD patients and analyzed them using LC-MS/MS-based proteomics to determine differential expression plasma proteins (DEPPs). Then, the DEPPs were subjected to a two-sample Mendelian randomization (MR) study based on an "Inverse variance weighted (IVW)" approach to investigate the causal relationships between DEPPs and LUAD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!